Abstract Introduction Although information on COVID-19 infection during pregnancy is still limited, existing evidence does not support increased susceptibility to infection or increased risk of developing severe disease during pregnancy, and the occurrence of intrauterine transmission has not been proven conclusively. However, to our knowledge, there is even less information available on co-infection with sexually transmitted infections in pregnant patients with COVID-19. The prevalence of any curable STI (gonorrhea, chlamydia, trichomoniasis, or syphilis) during pregnancy is estimated to be 3.3% (95% CI 2.9-3.7). Objectives STIprevalence may be correlated with COVID-19 infection in pregnant women, since both are influenced by risk-taking behaviors (i.e. condom use, mask-wearing, handwashing, and social distancing). On the other hand, an upregulated immune response in the setting of COVID-19 infection may in fact provide immunological protection against co-infection with STI’s or Group B Streptococcus (GBS), a non-sexually transmitted infection with a prevalence of 17.9% (95% CI 16.2-19.7) in pregnant patients. Our goal was to further explore this relationship. Methods We conducted a chart review of 34 pregnant patients with COVID-19, specifically looking at the incidence of antenatal STI’s and GBS. Results The mean age of the participants was 28.9 (SD 5.7) years, the mean gestational age at infection was 33.9 (SD 7.3) weeks, and the mean gestational age at delivery was 37.2 (SD 4.4) weeks. 26.5% (n=9) of patients tested positive for an STI, including gonorrhea (n=3), chlamydia (n=3), HPV (n=3), and trichomoniasis (n=2). 23.5% (n=8) tested positive for GBS infection. Conclusions The increased incidence of STI’s among pregnant women with COVID-19 compared to the expected incidence for any pregnant woman may suggest increased risks to this particular population that are worth investigating further. Disclosure No.